LABORATORY AND CLINICAL STUDIES ON T-1220

Abstract

The bacteriostatic activities of T-1220 against E. coli, Klebsiella, Pseudomonas aeruginosa, Enterobacter isolated from blood in the period between 1972 and 1976, and Enterobacter isolated from other clinical materials in 1975 at Keio University Hospital were evaluated by the agar plate two fold dilution method. The inoculum was a 10-2 dilution of heart infusion broth overnight culture.
T-1220 were more active than ampicillin but less active than cefazolin against E. coli and Klebsiella. The antibacterial activities of T-1220 against E. coli, Enterobacter and P. aeruginosa were similar or more than that of carbenicillin or sulbenicillin.
Out of 4 patients treated with T-1220 of 2 g to 16 g a day, each patients with urinary tract infection and angina lacunaris were successfully treated with 2 g to 6 g a day of T-1220. No side effect was detected.